Consolidated Research Institute for Advanced Science and Medical Care, Waseda University, 513, Wasedatsurumaki-cho, Shinjuku-ku, Tokyo 162-0041, Japan.
Anticancer Res. 2011 Jul;31(7):2447-52.
The object of this study was to investigate the clinical predictive capability of peripheral myeloid dendritic cells (DCs) in Wilms' tumor 1 (WT1) vaccine therapy for patients with gynaecological cancer.
Six patients with WT1/human leukocyte antigen (HLA)-A*2402-positive gynaecological cancer were included in this study. The patients received intradermal injections of a modified 9-mer WT1 peptide every week for 12 weeks. Peripheral blood samples were obtained at 0, 4, 8 and 12 weeks after the initial vaccination. Circulating DCs were detected by flow cytometry.
The frequencies of CD14(+)CD16(+)CD33(+)CD85(+) myeloid DCs were significantly higher in the therapeutically effective group than in therapeutically inert group (p<0.05).
These results suggested that myeloid DCs, which should be associated with inducing cytotoxic T-cells, provided additional prognostic information in the use of cancer peptide vaccine.
本研究旨在探讨外周血髓样树突状细胞（DCs）在妇科癌症患者 WT1 疫苗治疗中的临床预测能力。
本研究纳入了 6 例 WT1/hLA-A*2402 阳性妇科癌症患者。患者每周接受一次皮内注射改良 9 肽 WT1，共 12 周。在初次接种后 0、4、8 和 12 周采集外周血样本。通过流式细胞术检测循环 DCs。
治疗有效的患者组中 CD14+CD16+CD33+CD85+髓样 DC 的频率明显高于治疗无效的患者组（p<0.05）。
这些结果表明，髓样 DC 可能与诱导细胞毒性 T 细胞有关，为癌症肽疫苗的应用提供了额外的预后信息。
